New Breast Cancer Model for Testing Telomerase Inhibitors
Author Information
Author(s): Raymond E, Sun D, Izbicka E, Mangold G, Silvas E, Windle B, Sharma S, Soda H, Laurence R, Davidson K, Hoff D D Von
Primary Institution: Human Telomerase Working Group, Institute for Drug Development – Cancer Therapy and Research Center
Hypothesis
Can a human breast cancer model be established to evaluate the effects of telomerase inhibitors?
Conclusion
The study successfully established a breast cancer model that can evaluate telomerase inhibitors and showed that telomerase activity can be down-regulated by certain drugs.
Supporting Evidence
- Telomerase activity varies significantly among different human cancer cell lines.
- MCF7 breast cancer cells showed intermediate telomerase activity compared to HeLa cells.
- The new assay improved the characterization and quantification of telomerase activity.
Takeaway
Researchers created a new way to study breast cancer that helps test drugs that can stop cancer cells from growing by targeting telomerase.
Methodology
The study used a biotinylated-primer extension assay to measure telomerase activity in various breast cancer cell lines.
Limitations
The study focused on a limited number of cell lines and may not represent all breast cancer types.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website